The Efficacy of a Peptide-Nucleic Acid Solution (RETICULOSE™*) for the Treatment of Hepatitis A and Hepatitis B - A Preliminary Controlled Human Clinical Trial

Abstract

To complete this preliminary study 53 patients were chosen. All patients were screened, diagnosed for Hepatitis A or Hepatitis B and separated into treatment and control groups. All of the patients selected were in the early onset stage of their infection, and diagnosed for Hepatitis A or B by appropriate laboratory tests with special attention to Anti-HAV, IGM and HepB surface Antigen to carefully differentiate those with A from those with B. The treated patients received Reticulose for a 15 day period and the control patients received placebo injections of physiological saline. Reticulose patients with Hepatitis showed positive. 18 patients with Hepatitis B and 9 patients with Hepatitis A were treated with Reticulose, compared to 17 control patients with Hepatitis B and 9 control patients with Hepatitis A treated with placebo. Based upon laboratory findings of several parameters; Prothrombin times, Serum bilirubin, white blood cell (WBC count) and clinical observations; Reticulose treated patients appeared to show significant improvement. The bilirubin levels of 83% of patients with Hepatitis B, treated with Reticulose for 15 days were in normal range in 30 days. None of the control patients were within normal range after 30 days with placebo treatment. Of Hepatitis A patients treated with Reticulose, 100% showed normal bilirubin after 30 days. Of control patients with Hepatitis A, only 22% were in normal range after 30 days. The findings in this preliminary trial lead to the conclusion that Reticulose appears to significantly reduce the recovery time and return to normal for patients with an acute episode of Hepatitis A or B. Further study is indicated.

Get full access to this article

View all access options for this article.

References

Alarcon G.S. and Townes A.S. (1973). Arthritis in viral hepatitis; Johns Hopkins MedJ, 132:1

Bancroft W.H. , Snitbhan R. and Scott R.M. (1977). Transmission of hepatitis B virus to Gibbons by exposure to human saliva containing Hepatitis B surface antigen. J Infect Dis 135:79

Becker M.D. , Baptista A. and Scheuer P.J. (1970).Prognosis of chronic persistent Hepatitis. Lancet 1:53

Bhatnagar P.K. , Blum H.E. , Nitecke D. , Papas E. , Mitlich D.R. , Karals M.J. and Byas G.N. (1982). Immune response to synthetic peptide analogues of Hepatitis B surface antigen specific for the common alpha determinant. Proc Natl Acad Sci USA 779: 4400

Blum H.E. , Haase A.T. , Harris J.D. , Walker D. and Byas G.N. (1985). Asymetric replication of Hepatitis B virus DNA in human liver: demonstration of cytoplasmic minus-strand DNA by blot analysis and in situ hybridization. Virology 139:87

Chung WK , Yoo J.Y. , Sun H.S. , Lee H.Y. , Lee I.J. , Kim S.M. and Prince A.M. (1985). Prevention of perinatal transmission of Hepatitis B Virus: a comparison between the efficacy of passive and Nonpassive immunization in Korea. J Infect Dis 151:280

Corey L. and Holmes K.K. (1980). Sexual transmission of Hepatitis A in homosexual man. New EnglJ Med 302:435

Cornu C. , Lamy M.E. , Geubel A. and Galanti L. (1983). Persistence of immunoglobulin M aAntibody to Hepatitis A virus and relapse of Hepatitis A infection. EurJ Clin Microbiol 3:45

Defranchis R. , D'Arminio A. , Vecchi M. , Ronchi G. , Del Ninno E. , Parraveicini A. , Ferroni P. and Zanetti A.R. (1980). Chronic asymptomatic HBsAg carriers: histologic abnormalities and diagnostic and prognostic value of serologic markers to HBV. Gastroenterology 79:521

10.

Figus A. , Blum H.E. , Vyas G.N. , De Virgilis S. , Cao A. , Lippi M. , Lai E. and Balestrieri A. (1984). Hepatitis B viral nucleotide sequences in non-A, non-B or Hepatitis B virus-related chronic liver disease. Hepatology 4:364

11.

Fowler M J F , Monjardino J. , Tsequaye K.N. , Zuckerman A.J. and Thomas H.C. (1984). The mechanism of replication of Hepatitis B virus: evidence of asymetric replication of the two DNA strands. JMed Virol 203:83

12.

Galambos J.T. (1964). Chronic persisting Hepatitis. AmJ Dig Dis 9:817

13.

Heathcote J. and Sherlock S. (1973). Spread of acute type B Hepatitis in London. Lancet 1:1468

14.

Hughes J.V. , Stanton L.W. , Tomassini J.E. , LONG WJ and Scolnick E.M. (1984). Neutralizing monoclonal antibodies to Hepatitis A cirus: partial localization of a neutralizing antigenic site. J Virol 52:465

15.

Purcell R.H. and Gerin J.L. (1985). Prospects for second and third generation Hepatitis B vaccines. Hepatology 5:159 Scheirmann N. and Kuwert EK (1983). Uptake and elimination of Hepatitis B immunoglobulins after intramuscular application in man. Dev Biol Standard 54:347

16.

Scott R.M. , Snitbhan R. , Bancroft W.H. , Alter H.J. and Tingpalapong M. (1980). Experimental transmission of Hepatitis B cirus by semen and saliva. J Infect Dis 142:67

17.

Shattock A.G. , Irwin F.M. , Morgan B.M. , Hillary I.B. , Kelly M.G. , Fielding J.F. , and Weir D.G. (1985). Increased severity and morbidity of acute Hepatitis in drug abusers with simultaneously acquired Hepatitis B and Hepatitis D virus infections. Br Med J. 290:1377

18.

Stevens C.E. , Aach R.D. , Hollinger F.B. , Mosley J.W. , Szmuness W. , Kahn R. , Werch J. and Edwards V. (1984) Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B Hepatitis in transfusion Recipients: an analysis of the transfusion-transmitted virus study. Ann Inter Med 101:733

19.

Tabor E. (1985). Thethree viruses of non-A, non-B Hepatitis. Lancet 1:743

20.

Wiener M. , Enat R. , Gellei B. and Barzilai D. (1984). Bridging hepatic necrosis in acute viral Hepatitis . IsrJ Med Sci 20:33 Wong M.L. , Lehmann N.I. and Gust I.D. (1976). Detection of Hepatitis B surface antigen in saliva of patients with acute

21.

Hepatitis B, and of chronic carriers. Med J Aust 2:52 Yoshizawa H. , Itoh Y. , Iwakiri S. , Tsuda F. , Nakano S. , Miyakjawa Y. and Mayumi M. (1980). Diagnosis of type A Hepatitis by fecal IgA antibody against Hepatitis A antigen. Gastroenterology 78:114